Research Analysts Issue Forecasts for FULC FY2026 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Fulcrum Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($1.04) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Several other equities analysts have also commented on the company. Leerink Partners raised Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $12.00 in a report on Friday, May 23rd. Piper Sandler reissued an “overweight” rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Finally, Leerink Partnrs raised Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, May 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $6.29.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC opened at $6.83 on Wednesday. The firm has a market capitalization of $368.68 million, a PE ratio of -22.03 and a beta of 2.41. The business’s fifty day moving average price is $5.06 and its 200 day moving average price is $4.23. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC grew its holdings in shares of Fulcrum Therapeutics by 145.8% during the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock worth $189,000 after purchasing an additional 23,792 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics during the fourth quarter worth about $38,000. American Century Companies Inc. grew its holdings in shares of Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock worth $567,000 after buying an additional 6,770 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Fulcrum Therapeutics by 25.1% during the fourth quarter. Northern Trust Corp now owns 710,321 shares of the company’s stock worth $3,339,000 after buying an additional 142,578 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Fulcrum Therapeutics by 224.0% during the fourth quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock worth $358,000 after buying an additional 52,628 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.